Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
Status:
Terminated
Trial end date:
2017-06-02
Target enrollment:
Participant gender:
Summary
This is an open-label extension study for participants who completed a Phase 3,
placebo-controlled study of ataluren in participants with nonsense mutation cystic fibrosis
(nmCF) not receiving chronic inhaled aminoglycosides.